Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
DENVER, July 13, 2017 -- The International Association for the Study of Lung Cancer (IASLC) announced today that the IASLC 18th World Conference on Lung Cancer (WCLC) will take place on October 15-18, 2017, in Yokohama, Japan. The WCLC is the world’s largest meeting dedicated solely to lung cancer and other thoracic malignancies—gathering over 6,000 delegates from more than 100 countries to discuss the latest scientific advances in the field.
“Year after year, the WCLC is a must-attend event in the lung cancer community due to the quality of research presented and the singular focus on these particular malignancies,” said Fred Hirsch, MD, PhD, Professor of Medicine and Pathology at the University of Colorado Cancer Center and School of Medicine and CEO of the IASLC. “This is the premier lung cancer meeting of the year, and beyond disseminating new scientific achievements, the meeting also fosters global collaboration and networking. We look forward to gathering the brightest minds and to bringing the latest developments to the many patients who need it.”
The WCLC features a variety of programming that will explore deep insights across disciplines and specialties, including sessions on clinical trial results, targeted therapies, immunotherapy, prevention/screening, nursing and advocacy. The educational sessions and abstract presentations will highlight the latest advancements in treatment and breakthroughs in research.
Conference attendees include surgeons, medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, epidemiologists, basic research scientists, nurses, allied health professionals and industry representatives. The WCLC also welcomes lung cancer patients, survivors, caregivers and advocates, ensuring that all stakeholders have a voice.
For more information, please visit: http://wclc2017.iaslc.org/
About the WCLC:
The World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting over 6,000 researchers, physicians and specialists from more than 100 countries. The goal is to disseminate the latest scientific achievements; increase awareness, collaboration and understanding of lung cancer; and to help participants implement the latest developments across the globe. Organized under the theme of “Synergy to Conquer Lung Cancer,” the conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit http://wclc2017.iaslc.org/.
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.
Contact: Hillary Wasserman [email protected] +1 212.784.5726
